In gene ther­a­py's sec­ond big win this week, Or­chard nabs $110M Se­ries B

Lon­don start­up Or­chard Ther­a­peu­tics is join­ing the ranks of com­mer­cial-stage gene ther­a­py com­pa­nies with a new $110 mil­lion Se­ries B round to take its lead pro­gram through late-stage tri­als.

The round was led by Bail­lie Gif­ford and ORI Cap­i­tal, while Temasek, Cowen Health­care In­vest­ments, and ex­ist­ing in­vestors joined.

This week may mark a tide turn­ing for the gene ther­a­py crowd, which has been long-rid­dled by fail­ures and skep­ti­cism. Just yes­ter­day, the FDA rolled out a his­toric ap­proval for Spark Ther­a­peu­tics’ gene ther­a­py for blind­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER